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Purinergic receptors in skeletal muscles in health and in muscular dystrophy
ABSTRACT
The P2 purinergic (nucleotide) receptor super-family comprises of two families of protein. The P2X, which are channel-forming ionotropic receptors and the P2Y metabotropic re-
ceptors activating G protein-mediated signalling pathways. Members of both groups have 
been identified in skeletal muscle cells at different stages of differentiation. It is well docu-
mented that sequential expression and down-regulation of particular P2 receptors on the 
surface of sarcolemma is closely associated with muscle maturation during embryogenesis 
and postnatal growth. P2 receptors are also involved in muscle regeneration following in-
jury. Moreover, enhanced expression of specific purinergic receptors together with increased 
availability of extracellular ATP in dystrophic muscles are important elements of the dys-
trophic pathophysiology considerably increasing severity.
INTRODUCTION
Skeletal muscles (SM) are the most abundant type of muscle and considered 
the largest human organ as they account for at least 40% of body mass. However, 
despite morphological and functional similarities, specific muscle groups can 
differ significantly in their developmental origins and susceptibility to diseases 
(for review see: [1]). Indeed, muscle is a heterogeneous and metabolically dy-
namic structure, made of several kinds of tissues. Its main function, the body 
movement, can be controlled voluntarily. Due to specific properties including 
excitability, conductivity, extensibility and elasticity muscles are susceptible to 
excitation, signal transduction and propagation and fully reversible contraction. 
Skeletal muscles are not only responsible for movements but also allow main-
taining and stabilizing the posture and strengthening the joints of the skeleton. 
SM can also generate heat. Moreover, SM play an important metabolic role, par-
ticularly in the insulin-dependent regulation of glycaemia and glycogen storage 
and in fatty acid metabolism.
Fully differentiated muscle cells are multinucleated large fibres surrounded 
by a specialised cell membrane called sarcolemma and contain a very orderly ar-
rangement of myofibrilar proteins responsible for muscle contraction, large sar-
coplasmic reticulum and multiple mitochondria clustered in the subsarcolem-
mal and intermyofibrillar spaces.
All muscle functions occur at the expense of ATP produced in muscle cells but 
fibres differ in their preference for energy sources. Oxidative phosphorylation is 
a major source of ATP in the so called slow twitch or “red” muscle fibres while 
metabolism of the fast twitch (“white”) muscle relies on an anaerobic glycolysis. 
The proportion between fast and slow fibres decides about the energy metabo-
lism and physiological properties (fast or slow twitching) of particular muscles.
Molecular and metabolic differences determining muscle locus and metabolic 
properties appear during their differentiation, which is a multistep process origi-
nating from muscle progenitors called satellite cells (SC). SC reside underneath 
the basal lamina of muscle fibres and originate from somites — spheres of pa-
raxial mesoderm [1,2]. These mononuclear cells, when activated during either 
development or postnatal growth, divide in an asymmetrical fashion resulting 
in generation of another SC and a second cell subsequently differentiating into 
a myoblast. Myoblasts, when stimulated to differentiate, may fuse with a pre-
existing muscle fibre thus increasing its size and force of contraction or they may 
fuse with each other leading to formation of new muscle fibres. These processes 
are regulated by specific transcription factors, which expressions change in an 
orchestrated fashion with progression of differentiation in developing but also 
in a growing, adult SM.
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If muscle fibers become damaged, either due to injury 
or as a consequence of muscle diseases, adult SM also have 
the ability to regenerate. Thus, satellite cells are activated 
not only during physiological growth of muscle fibres but 
also under pathological conditions. They start to proliferate, 
migrate and fuse with pre-existing fibres and with each an-
other while undergoing differentiation to replace damaged 
fibres. The entire process can be accomplished within just a 
few days [3]. Fully differentiated myofibres are not capable 
of further division and remain in the G0 phase of the cell 
cycle.
Differentiation and maturation to myoblasts, myotubes 
and finally mature muscle fibres need numerous extracellu-
lar stimuli to be induced. Amongst these, it has been shown 
that differentiation is accompanied by quantitative and 
qualitative changes of nucleotide receptors. These involve 
both ionotropic (P2X) and metabotropic (P2Y) receptors and 
specific nucleotides, acting at these receptors, are important 
stimuli, which contribute to muscle cell differentiation (see 
below) [4,5].
PURINERGIC SIGNALLING IN SKELETAL MUSCLES
Nucleotides acting in autocrine or paracrine manner me-
diate cellular responses via purinergic P2 receptors located 
on the cell surface. These receptors belong to one of the two 
main families distributed in almost all mammalian tissues: 
the ionotropic receptors P2X(1-7), which are a heterogeneous 
group of ligand-gated, oligomeric ion channels, with seven 
subtypes identified so far [6,7] and the metabotropic (P2Y) 
G protein-coupled receptors family [8].
While the only natural agonist of P2X receptors is ATP, 
P2Y receptors are selectively sensitive to different purine 
and pyrimidine nucleotides. And so: P2Y1 is sensitive to 
ADP >ATP; P2Y2 to UTP ≥ ATP; P2Y4 to UTP ≥ ATP (rat) > 
CTP, ITP; P2Y6 to UDP > UTP >> ATP; P2Y11 to ATP; P2Y12 
to ADP; P2Y13 to ADP > ATP and P2Y14 to UDP UDPglu-
cose > UDP-galactose [for review see 8]. More details are 
also available in article by Barańska in this issue of Postępy 
Biochemii.
The role of purinergic receptors in muscle cells has been 
investigated for about 30 years, so the main principle of 
their action there seems to be understood. However, sur-
prisingly many aspects of nucleotide-evoked stimulation of 
SM, particularly under pathological conditions, still need to 
be clarified.
Susceptible to stimulation with extracellular nucleotides 
specific purinergic receptors participate in muscle cell dif-
ferentiation during embryogenesis, postnatal muscle forma-
tion and regeneration [9]. Intensity of cellular response to 
extracellular nucleotides depends on both the expression of 
particular receptor on the cell surface (which changes dur-
ing muscle maturation) and the presence of appropriate nu-
cleotides in the inter-cellular space. At the resting state, skel-
etal muscle has a rather low metabolic rate, with the cyto-
solic ATP concentration in the 5–10 mM range [10]. ATP can 
be released into the extracellular space in small amounts, as 
a response to or a consequence of muscle activity [11] or in 
large amounts following damage or death of muscle cells. 
Furthermore, nucleotide concentrations in the extracellular 
compartment are regulated by extracellular hydrolysing en-
zymes (nucleotidases). For example, ATPases, which cata-
lyse ATP degradation to ADP and further to adenosine.
Activation of all P2X and most of the P2Y receptors re-
sults in the increase in intracellular calcium concentrations 
([Ca2+]i). However, the relative contribution of specific re-
ceptors depends on the animal species, stage of embryonic 
and postnatal development and stage of muscle cell differ-
entiation.
Moreover, purinergic receptors are not only important 
under physiological conditions but they have a role in the 
pathogenesis of muscular dystrophies. This may involve en-
hancing Ca2+ entry into dystrophic muscle cells but also trig-
gering a unique mechanism of autophagic cells death [12] as 
found in the mdx (X chromosome-linked muscular dystro-
phy) mice as well as in the inflamasome response as shown 
in dysferlinopathy [13]. However, the relative importance 
or participation of specific purinergic receptors in these ab-
normalities has not been evaluated fully [14].
NUCLEOTIDE SIGNALLING AT  
THE NEURO-MUSCULAR JUNCTION
Nucleotides and nucleotide receptors play a role not 
only in muscle development and regeneration but also in 
signalling processes at the neuromuscular synapses. For 
example, ATP is released from the motor nerve terminals 
to the neuromuscular junction (NMJ) [15,16]. NMJ is a spe-
cialized, peripheral synapse between a lower motor neu-
ron and a SM fibre which allows muscle fibres to be excited 
by pre-synaptic motor nerves, leading to a rapid muscle 
contraction [17]. In the early NMJ development, ATP can 
be co-released with acetylocholine (ACh), which is the ma-
jor neurotransmitter in neuro-muscular synapses and ATP 
stimulates both P2 receptors and ACh nicotinic receptors 
located on the postsynaptic membrane [18,19]. Both ATP 
and ACh are released by exocytosis from synaptic vesicles 
in the pre-synaptic part [20] and ionotropic P2X7 receptors 
found in the mouse NMJ seem to activate this release from 
synaptic vesicles [21]. In addition, ATP co-released with 
ACh from the motor nerve terminals may play an impor-
tant role in the regulation of SM fibre volume [22]. It has 
also been shown that P2X2 receptors are expressed togeth-
er with ACh receptors (AChR) during NMJ development 
[4] and ATP is thought to stabilize the neuromuscular junc-
tion and may play a role in the synaptic modification dur-
ing development [19,23]. Apart from P2X, metabotropic 
P2Y1 receptors also seem to participate in the regulation 
of AChR in cultured chick myotubes. Co-localization of 
AChR and P2Y1 at the neuro-muscular synapses was also 
described [24].
Interestingly, in cultured muscle cells, which do not form 
neuro-muscular junctions because of the absence of inner-
vation, both ACh and P2Y1 receptors are distributed evenly 
all over the sarcolemma. It may suggest that innervation 
regulates spatial distribution of these receptors and it might 
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also indicate close functional interactions between these two 
proteins [14].
P2X RECEPTORS IN SKELETAL MUSCLE 
DEVELOPMENT, REGENERATION AND PATHOLOGY
P2X receptors mediate ATP signalling through the three 
main mechanisms: Primarily they function as trimeric li-
gand-gated cation channels but under specific conditions 
can contribute to the formation of a large pore and have the 
ability to form complexes with other proteins and mem-
brane lipids [25].
P2X subtypes vary in their sensitivity to agonist, regula-
tion and kinetics of action. However, all are Ca2+-permeable 
channel-forming proteins, thus their activation leads to ex-
tracellular calcium influx into the cell and elevation of cyto-
solic concentrations of this ion. Ca2+ entry due to activation 
of P2X receptors can also result in the plasma membrane de-
polarization, which in turn may reduce Ca2+ influx through 
the store-operated calcium channels partially driven by 
membrane potential (SOC) [26]. Thus, P2X-mediated eleva-
tion of the cytosolic Ca2+ concentration is a principal mecha-
nism of ATP signalling and one which is involved in various 
physiological processes across the body, such as synaptic 
plasticity, neurotransmitters release, smooth muscle con-
traction, cell proliferation or inter-cellular communication 
(reviewed in [25]).
While a short stimulation of P2X receptors leads to the 
opening of the ion channel, sustained stimulation with the 
agonist may contribute to the formation of a large-pore, 
with a permeability for molecules of several hundred dal-
tons, such as ethidium bromide or YO-PRO1 [27-29]. This 
property is mainly attributed to P2X7, however, other P2X 
receptors such as P2X2, P2X4, P2X2/3 and P2X2/5 hetero-oli-
gomers have also been analysed as potentially forming this 
large pore [25,30]. Moreover, several studies have suggest-
ed that other distinct protein(s) activated by P2X7 receptors 
may also contribute to this large-pore formation. Particu-
larly, the pannexin-1 channel attracted much attention [27] 
as its inhibition significantly suppressed the pore formation 
in both HEK293 cells and macrophages [27,31]. However, 
pannexin-1 channel has been reported to have no significant 
contribution to the large pore formation resulting from ac-
tivation of P2X2 or P2X4 receptors [32,33]. More recent data 
suggest that pannexin-1 may also form membrane-span-
ning pores without contribution from purinergic receptors 
in muscle cells [34].
P2X7 large pore formation has been shown to have an im-
portant role in several physiological and pathological pro-
cesses such as lymphocyte death, microglial proliferation 
or chronic pain (reviewed in [35]) and recently also in au-
tophagic death of dystrophic muscles [12], however its role 
as more Ca2+-selective calcium channel in healthy cells must 
not be ignored [21].
Given that ATP has a significant effect in skeletal muscle 
development it is interesting that specific subtypes of P2X 
receptors are sequentially expressed during myogenesis 
[36]. The expression pattern of P2X receptors in SM varies 
depending on the developmental stage and also animal spe-
cies studied. Expression of P2X1, P2X4, P2X5 and P2X6 has 
been demonstrated in developing chick myoblasts [37,38] 
while an expression of P2X2, P2X5 and P2X6 has been re-
ported in rat muscles [4]. Specifically, no P2X receptor has 
been reported to be expressed up to the E15 stage of the rat 
embryonic development. Immunoreactivity of P2X5 recep-
tors becomes detectable first at E15 in the small number of 
cells at the ends of muscles [4]. At E16, P2X6 expression ap-
pears. However, both P2X5 and P2X6 immunoreactivity dis-
appears by E20 [4]. In contrast, P2X2 starts to be expressed 
at E18, particularly in the lower limb SM and its immuno-
reactivity can be detected up to one week into the postnatal 
development [4]. Thus, P2X5 is the first ionotropic receptor, 
which is expressed during skeletal muscle development, 
followed by P2X6 and eventually by P2X2 (Fig. 1). Similar 
role of P2X5 receptors have previously been shown in pro-
liferating and developing striated squamous epithelia [39], 
which suggested that ATP play a role in these two processes 
in different tissues. Indeed, this ATP function has been re-
ported during muscle satellite cells differentiation, as P2X5 
activation inhibits their proliferation and promotes differ-
entiation by enhancing the phosphorylation of MAPK p38 
[40]. It has been demonstrated that activation of these recep-
tors by ATP contributes to the shift 
in the balance between satellite cells 
proliferation and differentiation. As 
shown in rat myoblasts, it reduced 
rate of proliferation with increased 
differentiation marker levels [40]. 
P2X4 receptors have been reported to 
localize inside T-tubule membranes 
in rat muscles [15], which could 
suggest some role in the excitation-
contraction coupling. P2X2, P2X4 and 
P2X7 receptors have been demon-
strated to be expressed in both myo-
blasts and myotubes, however, P2X2 
mRNA has only been detected in 
myotubes [36]. P2X7 and P2X4 recep-
tors were shown to be up-regulated 
upon cells differentiation, and spe-
cific heteromeric channel formation 
Figure 1. Temporal changes in P2 receptors in rat skeletal muscles [4,5]. P2Y4 receptor expressed postnatally is 
involved in muscle fibres maturation [5].
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between these subunits, which changes receptor pharma-
cology seems to be possible [41,42]. However, a precise role 
of P2X4 receptors in myoblasts is not fully understood [43].
Mechanical injury or inflammatory processes in muscles 
may damage muscle fibres and result in a local increase 
of extracellular concentrations of many intracellular com-
pounds, including ATP and other nucleotides. Such a sce-
nario is envisaged in various muscular dystrophies [44].
Muscular dystrophies are a class of genetic diseases af-
fecting various groups of human muscles and leading to 
disability. One of the most severe of these, and also the 
most common, is Duchenne muscular dystrophy (DMD). 
This disease, leading to a premature death of young adults 
is caused by the mutation(s) in the DMD gene encoding 
dystrophin protein [45,46]. Dystrophin is a cytoskeletal 
protein responsible for linking the actin cytoskeleton with 
membrane proteins, and indirectly, with extracellular ma-
trix. This arrangement is responsible for stabilizing muscle 
fibres during contraction and lack of dystrophin results in 
higher susceptibility of sarcolemma to damage [47,48]. Im-
portantly, in the early stages of Duchenne muscular dystro-
phy, muscle damage is followed by cycles of regeneration.
Together with ATP released from the motor nerve ter-
minals and from muscle fibres during contraction [49-51] 
nucleotides released due to a damage lead to an excessive 
extracellular ATP concentration (above 100 µM), which can-
not be efficiently counterbalanced by ecto-ATPases. One of 
proteins with ecto-ATPase activity is α-sarcoglycan, which 
is a component of a dystrophin-associated protein (DAP) 
complex found in skeletal muscles [52]. Improper assem-
bly of DAP in the absence of dystrophin result in a reduced 
amount of α-sarcoglycan on the cell surface and therefore 
less effective ATP degradation. Similarly, mutations in sar-
coglycan subunits, which cause specific muscle dystrophies 
e.g Limb-Girdle Muscular Dystrophy may be accompanied 
by increased concentrations of extracellular ATP.
Considering that skeletal muscles store more ATP than 
most tissues, it seems plausible that ecto-ATPases may be 
not able to cope with the effects of ATP overload in dys-
trophic muscles and various subtypes of P2 purinergic re-
ceptors may get over-activated. While low-level ATP plays 
a significant role in regulating skeletal muscle differentia-
tion under physiological conditions (as mentioned earlier) 
and also muscle fibre regeneration in disease [44], excessive 
stimulation of particular P2X receptors could aggravate pro-
gression and increase severity of muscle damage.
Regeneration of damaged muscle can occur as long as 
satellite cells are available and this process generally re-
sembles muscle development. However, local extracellu-
lar environment in regenerating muscle may substantially 
differ from that found under physiological/developmental 
conditions. It is usually influenced by the local inflamma-
tory response and the presence of immune cells, which are a 
source of many factors, including ATP, influencing muscle 
cells. Moreover, these cells also express purinergic recep-
tors. For example, DNA microarray analyses showed an up-
regulation of P2X4 transcripts in dystrophic skeletal muscle. 
However, this increase has eventually been shown to be 
due to the increased numbers of macrophages infiltrating 
the muscle [53] and thus the P2X4 overexpression found to 
be secondary to the damage of DMD fibres. P2X7 was also 
found both in human and mouse macrophages, however in 
the case of this receptor its presence in muscle cells has been 
convincingly confirmed [53,54]. This difference illustrate the 
complexity of purinergic signalling in dystrophic muscles. 
Moreover, apart from increased ATP levels, this disease is 
also characterized by increased expression of P2 receptors 
[54]. Such over-activation of P2X receptors due to increased 
agonist levels combined with specific overexpression were 
observed in muscles of the mdx mouse model of DMD. 
Therefore changes in P2X receptors activity could contrib-
ute to the abnormal cytosolic Ca2+ homeostasis, which has 
been found in this pathology [55].
Abnormal expression of P2X receptors is not unique to 
muscle disorders. Changes in the expression of distinct P2X 
have also been found in the inflammatory and chronic pain, 
epilepsy, depression and in some cancers [56] and this led 
to experimental therapeutic approaches with the use of P2X 
agonists [25,56]. Interestingly, overexpression of P2X7 re-
ceptor was also found in lymphoblasts from DMD patients, 
indicating non-muscle phenotypic manifestation of dystro-
phin deficiency [57].
In addition to P2X7, P2X2 and P2X5, normally absent 
from healthy skeletal muscle cells, have been observed in 
dystrophic mdx muscles [44]. As mentioned earlier, P2X5 re-
ceptors appear on satellite cells first, then followed by P2X2 
expression on newly formed myotubes. This may indicate 
accelerated differentiation of satellite cells in dystrophic 
mouse muscles.
P2Y RECEPTORS IN MUSCLE DEVELOPMENT 
AND REGENERATION
In contrast to ionotropic nucleotide receptors, which 
have been extensively investigated in skeletal muscles, the 
knowledge of P2Ys in this tissue is less comprehensive. Of 
the 12 members of the P2Y family, eight (P2Y1, P2Y2, P2Y4, 
P2Y6, P2Y11, P2Y12, P2Y13, and P2Y14) have been found in 
humans. Other four types represent either nonmammalian 
orthologs or orphan receptors with no evidence of being nu-
cleotide receptors ([58], for review see: [59]).
All P2Y receptors influence cell metabolism via interac-
tion with G-proteins and specificity for particular G-protein 
subtype determines mechanism of their action involving ei-
ther activation of calcium signalling by stimulation of phos-
pholipase C (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11) or inhibition of 
adenylate cyclase (P2Y11, P2Y12, P2Y13, P2Y14). P2Y11 may ex-
ert both activities. (To find more information read the article 
by Barańska in this issue of Postępy Biochemii). In terms of 
muscle physiology and pathophysiology most of the avail-
able data concern the first category while the knowledge of 
nucleotide receptors acting via adenylate cyclase is rather 
limited. Moreover, the P2Y effects in skeletal muscles seem 
to be species-specific. For example, it was suggested that ac-
tivation of P2Y13, a receptor highly sensitive to ADP, stimu-
lates Na,K-ATPase functions in rat skeletal muscle. In con-
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trast, stimulation of P2Y11 (absent from rat muscles), which 
is relatively less sensitive to ADP, resulted in an inhibition 
of Na,K-ATPase activity in human muscles. Thus, species-
specific expression of particular receptors determines cellu-
lar response to the same stimulus [60].
It is well established that P2Y expression in muscle cells 
(similarly to P2X) varies with the developmental stage. For 
example, during rat embryonic skeletal muscle develop-
ment three metabotropic receptors, P2Y1, P2Y2 and P2Y4 
were identified. Their expression patterns change along pro-
gression of the early muscle formation. The expression of 
the P2Y1 and P2Y4 receptors begins at E11 and of P2Y2 at E12 
and it is correlated with an appearance of myoblasts-specific 
markers. All three receptors were exclusively detectable in 
myotome. After next few days of embryonic development 
(by E18) P2Y1 and P2Y2 receptors expression was down-
regulated while expression of P2Y4 ceased postnatally [5]. It 
has been suggested that such patterns of P2Y expression are 
important for activation and regulation of sequential steps 
of muscle formation, including proliferation of muscle pro-
genitors, migration and fusion [61].
Similar studies of muscle formation in mice have also re-
vealed participation of the P2Y6 receptor. Its expression in 
the dermamyotome appeared at E9 and from E15 and post-
natally it gradually declined. The expression of P2Y6 is also 
temporarily activated during regeneration of injured mouse 
muscle [62].
Despite intensive studies the role of P2Y receptors in SM 
both in health and disease in men and animal models is still 
poorly understood where we have but fragmented pieces of 
data. For example, Borno et al. [7] demonstrated the presence 
of P2Y4 and P2Y11 receptors in human muscle using Western 
blotting. Furthermore, at the transcriptional level, P2Y1 and 
P2Y2 receptors were identified in human skeletal muscles 
[63]. Ryten et al. [44] working with mouse primary muscle 
cells showed expression of the P2Y1 receptor in mononu-
clear cells and early myotubes, whilst P2Y4 receptors were 
only expressed in myotubes. Presence of P2Y1 and P2Y4 in 
mouse myotubes was also described by others [14]. Some 
differences and apparent discrepancies between available 
experimental data concerning P2Y expression and activity 
may be explained at least partially by temporal changes in 
the expression of P2Y receptors, which are specific for par-
ticular cell stages. Moreover, differences between P2Y ex-
pression patterns due to analyses being performed in vari-
ous species must also be considered.
Changes in the P2Y expression profile were also demon-
strated in vitro, in C2C12 murine cells [36]. Transcripts 
encoding for P2Y1, P2Y2, P2Y4, P2Y6 and P2Y12, the latter 
activating adenylate cyclase, were identified in both myo-
blasts and myotubes. However, the expression of particular 
mRNAs changes during differentiation. In myoblasts, the 
mRNA encoding P2Y1, P2Y4 and particularly P2Y2 predom-
inated while expression of P2Y6, and P2Y12 was relatively 
lower. In myotubes, P2Y1, P2Y12, P2Y4 and P2Y6 were sub-
stantially reduced. These receptors are sensitive to ADP, 
UTP and UDP, respectively. In contrast, expression and ac-
tivity of ATP-sensitive P2Y2 receptor was unchanged and 
still high in myotubes [36].
Considering P2Y in SM functions, Banachewicz et al. [36] 
showed that ATP stimulated a rapid and transient increase 
of level of phosphorylated p42/ERK2 and p44/ERK1 in 
myotubes and myoblasts. Activation of ERK1/2 in myo-
tubes was due to P2Y2 activity and this effect was dependent 
on Ca2+. Authors demonstrated that all nucleotides activat-
ed ERK1/2, but stimulation of cells with UDP produced the 
lowest phosphorylation level of ERKs. In these myoblasts 
ERK1/2 activation seems to be dependent on P2X5. Further-
more, these effects were dependent on Ca2+ ions, because 
lack of extracellular Ca2+ strongly inhibited ERK1/2 activa-
tion [36]. However it must be noted that in dystrophic mu-
rine myoblasts (mdx) stimulation of P2X receptors, which are 
exclusively sensitive to ATP ,was found to activate ERK1/2 
phosphorylation in the Ca2+-independent manner [54]. It 
was also shown that that the P2Y6 receptor activation sig-
nificantly reduced the dramatic elevation of NF-κB induced 
by TNF-α in C2C12 myoblasts while it did not affect NF-κB 
level in untreated cells [64]. Moreover stimulation of P2Y6 
receptor evoked attenuation of TNF-α apoptosis in mouse 
skeletal muscle, which was accompanied with ERK1/2 acti-
vation [64]. However, conformation and complete explana-
tion of antiapoptotic role of P2Y6 in myoblasts in vivo needs 
further investigation.
To summarize, both P2X and P2Y nucleotide receptors 
are currently a focus of attention due to their widespread 
expression and the significant role they play in various 
physiological processes in different cells. Additionally, mul-
tiple reports showed that some of these purinergic receptors 
play a role in the Duchenne muscular dystrophy pathology. 
Complete understanding of their involvement needs further 
investigations. It cannot be excluded that they offer a po-
tential therapeutic target for stimulation of skeletal muscle 
regeneration after injury or in treatment of muscular dys-
trophy.
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STRESZCZENIE
Nadrodzina receptorów purynergicznych (nukleotydowych) składa się z dwóch rodzin białek. P2X są receptorami jonotropowymi tworzącymi 
kanały jonowe natomiast P2Y są receptorami metabotropowymi aktywującymi szlaki sygnałowe zależne od trimerycznych białek G. Wystę-
powanie przedstawicieli obu rodzin w komórkach mięśni jest niejednakowe i zależy od etapu ich różnicowania. Istnieją dowody wskazujące 
na to, że sekwencyjne pojawianie się tych białek oraz zmiana ich względnych ilości w sarkolemie są ściśle związane z tworzeniem się mięśni 
podczas rozwoju embrionalnego oraz ich wzrostu w okresie postnatalnym. Receptory nukleotydowe uczestniczą także w regulacji regeneracji 
mięśni po uszkodzeniu. Ponadto, zwiększona ekspresja genów kodujących specyficzne receptory nukleotydowe wraz ze zwiększonym stęże-
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